Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors

Monday, June 22, 2026

20:00–21:30 BST

This educational activity is independently supported by Eli Lilly. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Agenda

CME accreditation badge

This program has been accredited for 1.5 hours of CME credit.

Learning objectives

Following the symposium, learners will be able to: 

  • Describe clinically relevant differences between BTK inhibitors, including covalent and non-covalent binding and selectivity, and their implications for treatment of CLL.
  • Recall key clinical data supporting BTK inhibitor-based treatment strategies for first-line and relapsed/refractory CLL.
  • Apply evidence-based considerations for selecting BTK inhibitor-based treatment strategies for patients with CLL, considering prior therapies, disease and molecular risk features, resistance mutations, comorbidities, and patient-related factors.
  • Discuss the role of BTK inhibitors within evolving treatment paradigms for CLL.

Our speakers

Gilles Salles

Memorial Sloan Kettering Cancer Center
New York, US

Susan O’Brien

University of California, Irvine
Irvine, US

Farrukh Awan

University of Texas Southwestern Medical Center
Dallas, US

Francesc Bosch

University Hospital Vall d’Hebron
Barcelona, ES

About SES

Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.

Visit SES

About the Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma & CLL. Our aim is to enhance knowledge in lymphoma & CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage with treatment teams and researchers around the world.

Visit the Lymphoma Hub

Registration form

Registration is free.

Required fields

Thank you!

You have successfully registered for the webinar.

Please check your email for further information on how to attend.

Add to Calendar